Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8649687 | Clínica e Investigación en Arteriosclerosis | 2018 | 6 Pages |
Abstract
The clinical trials evaluated included a total of 16,112 patients (13 trials). The meta-analysis (including all the trials with fibrates) showed evidence of a protective effect of the fibrates compared with placebo as regards a compound objective of non-fatal stroke, non-fatal myocardial infarction, and death of cardiovascular origin (hazard ration of 0.88, with a 95% confidence interval of 0.83 to 0.94; in 16,064 individuals included in 12 studies). Thus, the results showed, with a moderate level of evidence, that fibrates could be effective in secondary prevention considering a compound objective of non-fatal stroke, non-fatal myocardial infarction, and death of cardiovascular origin.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Physiology
Authors
Jesus Millan, Xavier Pintó, Angel Brea, Mariano Blasco, Antonio Hernández-Mijares, Juan Ascaso, Angel Diaz, Teresa Mantilla, Juan Pedro-Botet,